Association of Lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2011, Pages 78-83

  Hirschler, Valeria ^a   Meroño, Tomas ^b   Maccallini, Gustavo ^a   Rosso, Leonardo Gomez ^b   Aranda, Claudio ^a   Brites, Fernando ^b  

^a HOSPITAL DURAND   (Argentina)

^b Laboratory of Free Radical Biology   (Argentina)

Author keywords

Adolescents; Apo B; Atherosclerosis; Cardiovascular disease; CETP; Children; Insulin resistance; Lipoprotein profile; Lp PLA2; Metabolic syndrome; Obesity

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE; MALE; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; APOLIPOPROTEINS B; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; ENZYME ACTIVATION; HUMANS; INSULIN RESISTANCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 79959973888     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152511796196542     Document Type: Article

References (33)

1. Libby, P.; Ridker, P.M.; Hansson, G.K. Inflammation in atheroscle rosis: from pathophysiology to practice. J. Am. Coll. Cardiol., 2009, 54(23), 2129-2138.
2. Thompson, A.; Gao, P.; Orfei, L.; Watson, S.; Di Angelantonio, E.;Kaptoge, S.; Ballantyne, C.; Cannon, C.P.; Criqui, M.; Cushman, M.; Hofman, A.; Packard, C.; Thompson, S.G.; Collins, R.; Danesh, J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 2010, 375(9725), 1536-1544.
3. Corson, M.A.; Jones, P.H.; Davidson, M.H. Review of the evidencefor the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am. J. Cardiol., 2008, 101(12A), 41F-50F.
4. Davidson, M.H.; Corson, M.A.; Alberts, M.J.; Anderson, J. L.; Gorelick, P. B.; Jones, P. H.; Lerman, A.; McConnell, J.P.; Wein-traub, H. S. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am. J. Cardiol., 2008, 101(12A), 51F-57F.
5. Kolodgie, F.D.; Burke, A.P.; Skorija, K.S.; Ladich, E.; Kutys, R.; Makuria, A. T.; Virmani, R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2006, 26(11),2523-2529.
6. Herrmann, J.; Mannheim, D.; Wohlert, C.; Versari, D.; Meyer, F. B.; McConnell, J.P.; Gossl, M.; Lerman, L. O.; Lerman, A. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur. Heart J., 2009, 30(23), 2930-2938.
7. Hatoum, I.J.; Nelson, J.J.; Cook, N.R.; Hu, F.B.; Rimm, E. B. Die-tary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am. J. Clin. Nutr., 2010, 91(3), 786-793.
8. Iribarren, C. Lipoprotein-associated phospholipase A2 andC-reactive protein for measurement of inflammatory risk: independent or complementary? Curr. Cardio. Risk Rep., 2010, 4, 57-67.
9. Gazi, I.; Lourida, E.S.; Filippatos, T.; Tsimihodimos, V.; Elisaf, M.; Tselepis, A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem., 2005, 51(12), 2264-2273.
10. Hirschler, V.;, T.; Maccallini, G.; Gomez Rosso, L.; Aranda, C.; Brites, F. Impact of unhealthy lifestyle behaviors and obesity on cholesteryl ester transfer protein among adolescent males. Arch Med. Res., 2011, 42(1), 53-59.
11. Chapman, M.J.; Le Goff, W.; Guerin, M.; Kontush, A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J., 2010, 31(2), 149-164.
12. Hirschler, V.; Roque, M.I.; Calcagno, M.L.; Gonzalez, C.; Aranda, C. Maternal waist circumference and the prediction of children's metabolic syndrome. Arch Pediatr. Adolesc. Med., 2007, 161(12), 1205-1210.
13. Kuczmarski, R.J.; Ogden, C.L.; Guo, S.S.; Grummer-Strawn, L.M.; Flegal, K.M.; Mei, Z.; Wei, R.; Curtin, L.R.; Roche, A.F.; Johnson, C.L. 2000 CDC Growth Charts for the United States: methods and development. Vital. Health Stat. 11., 2002, (246), 1-190.
14. National Institutes of Health (NIH). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. NIH publication, 1998, 98-4083.
15. Zimmet, P.; Alberti, K.G.; Kaufman, F.; Tajima, N.; Silink, M.; Arslanian, S.; Wong, G.; Bennett, P.; Shaw, J.; Caprio, S. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr. Diabetes, 2007, 8(5), 299-306.
16. National High Blood Pressure Education Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics, 2004, 114(2 Suppl. 4th Report), 555-576.
17. Tanner, J. Growth at Adolescence: With a General Consideration of the Effects of Hereditary and Environmental Factors upon Growth and Maturation from Birth to maturity; Blackwell Scientific: Oxford, UK, 1962.
18. Willett, W. Nutritional Epidemiology, Oxford University Press: New York, USA, 1998.
19. McAuley, K.A.; Williams, S.M.; Mann, J.I.; Walker, R.J.; Lewis-Barned, N.J.; Temple, L.A.; Duncan, A.W. Diagnosing insulin resistance in the general population. Diabetes Care, 2001, 24(3), 460-464.
20. Lagrost, L.; Gandjini, H.; Athias, A.; Guyard-Dangremont, V.; Lallemant, C.; Gambert, P. Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in nor-molipidemic subjects. Arterioscler. Thromb., 1993, 13(6), 815-825.
21. Blank, M.L.; Hall, M.N.; Cress, E.A.; Snyder, F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhy-drolase: higher activities in hypertensive rats. Biochem. Biophys. Res. Commun., 1983, 113(2), 666-671.
22. Wilensky, R.L.; Macphee, C.H. Lipoprotein-associated phospholipase A2 and atherosclerosis. Curr. Opin. Lipidol., 2009, 20(5), 415-420.
23. Burke, A.P.; Farb, A.; Pestaner, J.; Malcom, G.T.; Zieske, A.; Kutys, R.; Smialek, J.; Virmani, R. Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. Circulation, 2002, 105(4), 419-424.
24. Nagel, G.; Rapp, K.; Wabitsch, M.; Buchele, G.; Kroke, A.; Zollner, I.; Weiland, S.K.; Koenig, W. Prevalence and cluster of cardio-metabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany. Clin. Chem., 2008, 54(2), 317-325.
25. Okada, T.; Miyashita, M.; Kuromori, Y.; Iwata, F.; Harada, K.; Hattori, H. Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. Arterioscler. Thromb. Vasc. Biol., 2006, 26(5), e40-41.
26. Tsimikas, S.; Willeit, J.; Knoflach, M.; Mayr, M.; Egger, G.; Not-durfter, M.; Witztum, J.L.; Wiedermann, C.J.; Xu, Q.; Kiechl, S. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur. Heart J., 2009, 30(1), 107-115.
27. Persson, M.; Hedblad, B.; Nelson, J.J.; Berglund, G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler. Thromb. Vasc. Biol., 2007, 27(6), 1411-1416.
28. Saougos, V.G.; Tambaki, A.P.; Kalogirou, M.; Kostapanos, M.; Gazi, I.F.; Wolfert, R.L.; Elisaf, M.; Tselepis, A.D. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholi-pase A2. Arterioscler. Thromb. Vasc. Biol., 2007, 27(10), 2236-2243.
29. Rosenson, R.S. Fenofibrate reduces lipoprotein associated phos-pholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am. Heart J., 2008, 155(3), 499. e9-e16.
30. McLaughlin, T.; Reaven, G.; Abbasi, F.; Lamendola, C.; Saad, M.; Waters, D.; Simon, J.; Krauss, R.M. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am. J. Cardiol., 2005, 96(3), 399-404.
31. Talmud, P.J.; Edwards, K.L.; Turner, C.M.; Newman, B.; Palmen, J.M.; Humphries, S.E.; Austin, M.A. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation, 2000, 101(21), 2461-2466.
32. Skoglund-Andersson, C.; Ehrenborg, E.; Fisher, R.M.; Olivecrona, G.; Hamsten, A.; Karpe, F. Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men. Atherosclerosis, 2003, 167(2), 311-317.
33. Hogue, J.C.; Lamarche, B.; Gaudet, D.; Lariviere, M.; Tremblay, A.J.; Bergeron, J.; Lemieux, I.; Despres, J.P.; Gagne, C.; Couture, P. Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. J. Lipid. Res., 2004, 45(6), 1077-1083.